Here’s whether Bristol-Myers Squibb Co. (BMY) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Neutral.
🔵
Neutral
Positives: trading above the 200-day MA (long-term uptrend intact); RSI 41 — healthy momentum range; strong 1-year return of +12.7%. Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-1.01% over 10 days). Currently 9.2% off its 52-week high. Score: +2/7.
BMY is holding above its long-term 200-day MA ($53.42) but has slipped below the 50-day MA ($57.65), pointing to short-term weakness in an otherwise intact trend. An RSI of 41.3 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +12.7% compares to +22.9% for SPY (trailed the market by 10.2%).
$10,000 invested 1 year ago→ $11,270 today
vs. S&P 500 (SPY) — same period trailed market by 10.2%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($53.42)
✗Above 50-day MA ($57.65)
✓RSI(14) neutral zone (30–70) — currently 41.3
✓Positive return (+12.7%)
✓Within 10% of period high (−9.2%)
Period Range $57.13
$42.52$62.89
RSI (14) 41.3
0 · OversoldOverbought · 100
Key Metrics
Price$57.13
Period Return+12.7%
Period High$62.89
Period Low$42.52
Drawdown−9.2%
MA-50$57.65
MA-200$53.42
RSI (14)41.3
Avg Volume (30d)11.1M
vs. SPYtrailed by 10.2%
Return Rank#587 of 1246
Trend Signals
Price is above the 200-day moving average ($53.42)